All Releases
 |
Regeneron Announces Presentation at the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference
Aug 5, 2010
|
8.2 KB |
| |
TARRYTOWN, N.Y., Aug 05, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference on Friday, August 13, 2010. The presentation is scheduled for 11:20 a.m. Eastern Time. The session may be accessed through...
|
|
Astellas to Pay $295 Million to Extend License of Regeneron's VelocImmune(R) Antibody Technology through 2023
Jul 28, 2010
|
12.7 KB |
| |
TARRYTOWN, N.Y. and TOKYO, July 28, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. ("Regeneron"; Nasdaq: REGN) and Astellas Pharma Inc. ("Astellas"; Headquarters: Tokyo, Japan; President & CEO: Masafumi Nogimori) announced today that Astellas has extended through 2023 the non-exclusive license agreement that allows Ast...
|
|
Regeneron Reports Second Quarter 2010 Financial and Operating Results
Jul 28, 2010
|
31.3 KB |
| |
TARRYTOWN, N.Y., July 28, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial and operating results for the second quarter of 2010. The Company reported a net loss of $25.5 million, or $0.31 per share (basic and diluted), for the second quarter of 2010 compared with a net loss of $1...
|
|
Regeneron to Webcast Investor Day on July 15, 2010
Jul 13, 2010
|
9.7 KB |
| |
TARRYTOWN, N.Y., July 13, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that its Investor Day in New York City, to be held on Thursday, July 15, 2010, will be webcast live on the Company's website, www.regeneron.com, on the Investor Relations home page. The presentations will begin at 9...
|
|
Regeneron Announces Presentation at the Goldman Sachs 31st Annual Global Healthcare Conference
Jun 11, 2010
|
8.4 KB |
| |
TARRYTOWN, N.Y., June 11, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Goldman Sachs 31st Annual Global Healthcare Conference on Wednesday, June 16, 2010. The presentation is scheduled for 5:40 p.m. Eastern Time. The session may be accessed through the Company's w...
|
|
ARCALYST(R) (rilonacept) Meets Primary and All Secondary Endpoints in Phase 3 Trial of Prevention of Gout Flares in Patients Initiating Allopurinol Therapy
Jun 9, 2010
|
20.8 KB |
| |
TARRYTOWN, N.Y., June 9, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that a Phase 3 study in gout patients initiating allopurinol therapy to lower their uric acid levels showed that ARCALYST (rilonacept), also known as IL-1 Trap, prevented gout attacks, as measured by the primary endpo...
|
|
Regeneron Schedules June 9, 2010 Teleconference and Webcast to Discuss Phase 3 Trial Results in Gout
Jun 8, 2010
|
8.8 KB |
| |
TARRYTOWN, N.Y., June 8, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time tomorrow, Wednesday, June 9, to discuss Phase 3 trial results for ARCALYST(R) (rilonacept) in the prevention of drug-induced gout flares and in ...
|
|
Regeneron Announces Presentation at the 9th Annual Needham Healthcare Conference
Jun 4, 2010
|
8.1 KB |
| |
TARRYTOWN, N.Y., June 4, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the 9th Annual Needham Healthcare Conference on Thursday, June 10, 2010. The presentation is scheduled for 2:00 p.m. Eastern Time. The session may be accessed through the Company's web site, www.reg...
|
|
Regeneron Announces Presentation at the 2010 Citi Investment Research Global Healthcare Conference
May 20, 2010
|
8.1 KB |
| |
TARRYTOWN, N.Y., May 20, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the 2010 Citi Investment Research Global Healthcare Conference on Wednesday, May 26, 2010. The presentation is scheduled for 9:00 a.m. Eastern Time. The session may be accessed through the Company's...
|
|
Regeneron Provides Initial Data on Two Antibody Product Candidates
May 12, 2010
|
13.8 KB |
| |
TARRYTOWN, N.Y., May 12, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today provided an update on two antibody product candidates in its pipeline and scheduled its first Investor Day to be held in New York City on July 15, 2010. Both product candidates, REGN727 (SAR236553) and, REGN475 (SAR164877) are...
|
|
Regeneron Announces Participation in J. P. Morgan Biotech: CEO/CFO Conference Call Series
May 11, 2010
|
8.3 KB |
| |
TARRYTOWN, N.Y., May 11, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will participate in the J. P. Morgan Biotech: CEO/CFO Conference Call Series at 10:00 a.m. Eastern Time on Friday, May 14, 2010.
Conference call details are as follows:
Live conference call (US): (888) 889-1309 Live conference cal...
|
|
Regeneron Announces Presentation at the Bank of America Merrill Lynch 2010 Healthcare Conference
May 7, 2010
|
8.4 KB |
| |
TARRYTOWN, N.Y., May 7, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Bank of America Merrill Lynch 2010 Healthcare Conference on Thursday, May 13, 2010. The presentation is scheduled for 1:00 p.m. Eastern Time. The session may be accessed through the Company's web...
|
|
Regeneron Reports First Quarter 2010 Financial and Operating Results
Apr 29, 2010
|
26.4 KB |
| |
TARRYTOWN, N.Y., April 29, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial and operating results for the first quarter of 2010. The Company reported a net loss of $30.5 million, or $0.38 per share (basic and diluted), for the first quarter of 2010 compared with a net loss of $15...
|
|
Regeneron Announces Appointment of Michael Aberman, M.D., as Vice President, Strategy and Investor Relations
Mar 22, 2010
|
10.8 KB |
| |
TARRYTOWN, N.Y., March 22, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the appointment of Michael Aberman, M.D., as Vice President, Strategy and Investor Relations. In the Strategy role, Dr. Aberman will report directly to Leonard S. Schleifer, M.D., Ph.D., President and Chief Executi...
|
|
Regeneron Announces Presentation at the Barclays Capital Global 2010 Healthcare Conference
Mar 18, 2010
|
8.3 KB |
| |
TARRYTOWN, N.Y., March 18, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Barclays Capital Global 2010 Healthcare Conference on Tuesday, March 23, 2010. The presentation is scheduled for 10:15 a.m. Eastern Time. The session may be accessed through the Company's web ...
|
|
Regeneron Announces Presentation at the Cowen and Company 30th Annual Healthcare Conference
Mar 4, 2010
|
8.1 KB |
| |
TARRYTOWN, N.Y., March 4, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Cowen and Company 30th Annual Healthcare Conference on Tuesday, March 9, 2010. The presentation is scheduled for 11:05 a.m. Eastern Time. The session may be accessed through the Company's web s...
|
|
Regeneron Announces Participation in a Panel Discussion at RBC Capital Markets Healthcare Conference
Feb 25, 2010
|
8.4 KB |
| |
TARRYTOWN, N.Y., Feb 25, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will participate in a webcast panel discussion on the topic "Building a Proprietary and Partnered Pipeline of Antibodies" at the RBC Capital Markets Healthcare Conference on Wednesday, March 3, 2010. The panel discussion will be br...
|
|
Regeneron Reports Full Year and Fourth Quarter 2009 Financial and Operating Results
Feb 18, 2010
|
29.3 KB |
| |
TARRYTOWN, N.Y., Feb 18, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial and operating results for the full year and fourth quarter of 2009. The Company reported a net loss of $67.8 million, or $0.85 per share (basic and diluted), for the year ended December 31, 2009 compared w...
|
|
VEGF Trap-Eye Shows Positive Results in a Phase 2 Study in Patients With Diabetic Macular Edema
Feb 18, 2010
|
18.5 KB |
| |
TARRYTOWN, N.Y. and LEVERKUSEN, Germany, Feb 18, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare AG today announced that VEGF Trap-Eye showed positive results in a Phase 2 study in patients with diabetic macular edema (DME). The primary endpoint of the study, a statistically signifi...
|
|
Regeneron Announces Presentation at the 28th Annual J.P. Morgan Healthcare Conference
Jan 7, 2010
|
7.9 KB |
| |
TARRYTOWN, N.Y., Jan 07, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the 28th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2010. The presentation is scheduled for 1:00 p.m. Eastern Time. The session may be accessed through the Company's web sit...
|
|
|
